Edvinsson L (2022) Calcitonin gene-related peptide (CGRP) is a key molecule released in acute migraine attacks-successful translation of basic science to clinical practice. J Intern Med 292:575–586

Article  CAS  PubMed  PubMed Central  Google Scholar 

Russo AF, Hay DL. CGRP physiology, pharmacology, and therapeutic targets: migraine and beyond. Physiol Rev. 2023;103(2):1565–644.

Sacco S, Amin FM, Ashina M, Bendtsen L, Deligianni CI, Gil-Gouveia R, Katsarava Z, MaassenVanDenBrink A, Martelletti P, Mitsikostas DD, Ornello R, Reuter U, Sanchez-Del-Rio M, Sinclair AJ, Terwindt G, Uluduz D, Versijpt J, Lampl C (2022) European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention – 2022 update. J Headache Pain 11(1):67

Article  Google Scholar 

Fiedler-Kelly J, Passarell J, Ludwig E et al (2020) Effect of fremanezumab monthly and quarterly doses on efficacy responses. Headache 60(7):1376–1391

Article  PubMed  PubMed Central  Google Scholar 

Ashina M (2020) Migraine. N Engl J Med 383(19):1866–1876

Article  CAS  PubMed  Google Scholar 

Raffaelli B, Fitzek M, Overeem LH, Storch E, Terhart M, Reuter U (2023) Clinical evaluation of super-responders vs. non-responders to CGRP(-receptor) monoclonal antibodies: a real-world experience. J Headache Pain 27(1):16

Article  Google Scholar 

Iannone LF, Fattori D, Marangoni M, Benemei S, Chiarugi A, Geppetti P, De Cesaris F (2023) Switching OnabotulinumtoxinA to monoclonal anti-CGRP antibodies in drug-resistant chronic migraine. CNS Drugs 37(2):189–202

Article  CAS  PubMed  Google Scholar 

Torres-Ferrús M, Gallardo VJ, Alpuente A, Caronna E, Gine-Cipres E, Pozo-Rosich P (2021) The impact of anti-CGRP monoclonal antibodies in resistant migraine patients: a real-world evidence observational study. J Neurol 268(10):3789–3798

Article  PubMed  Google Scholar 

Vandervorst F, Van Deun L, Van Dycke A, Paemeleire K, Reuter U, Schoenen J, Versijpt J (2021) CGRP monoclonal antibodies in migraine: an efficacy and tolerability comparison with standard prophylactic drugs. J Headache Pain 22(1):128

Article  CAS  PubMed  PubMed Central  Google Scholar 

Barbanti P, Egeo G, Aurilia C, Altamura C, d’Onofrio F, Finocchi C, Albanese M, Aguggia M, Rao R, Zucco M, Frediani F, Filippi M, Messina R, Cevoli S, Carnevale A, Fiorentini G, Messina S, Bono F, Torelli P, Proietti S, Bonassi S, Vernieri F (2022) Italian migraine registry study group. Predictors of response to anti-CGRP monoclonal antibodies: a 24-week, multicenter, prospective study on 864 migraine patients. J Headache Pain 23(1):138

Article  CAS  PubMed  PubMed Central  Google Scholar 

Al-Hassany L, Lyons HS, Boucherie DM, Farham F, Lange KS, Marschollek K, Onan D, Pensato U, Storch E, Torrente A, Waliszewska-Prosół M, Reuter U (2023) European Headache Federation School of Advanced Studies (EHF-SAS). The sense of stopping migraine prophylaxis. J Headache Pain 24(1):9

Article  PubMed  PubMed Central  Google Scholar 

Barbanti P, Aurilia C, Egeo G, Torelli P, Proietti S, Cevoli S, Bonassi S (2023) Italian Migraine Registry study group. Late response to Anti-CGRP monoclonal antibodies in migraine: a multicenter prospective observational study. Neurology 101(11):482–488

Article  CAS  PubMed  Google Scholar 

di Schiano F, Bolchini M, Ceccardi G, Caratozzolo S, Liberini P, Rao R, Padovani A (2023) An observational study on monoclonal antibodies against calcitonin-gene-related peptide and its receptor. Eur J Neurol 30(6):1764–1773

Article  Google Scholar 

Lampl C, MaassenVanDenBrink A, Deligianni CI, Gil-Gouveia R, Jassal T, Sanchez-Del-Rio M, Reuter U, Uluduz D, Versijpt J, Zeraatkar D, Sacco S (2023) The comparative effectiveness of migraine preventive drugs: a systematic review and network meta-analysis. J Headache Pain 24(1):56

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ziegeler C, May A (2020) Non-responders to treatment with antibodies to the CGRP-receptor may profit from a switch of antibody class. Headache 60(2):469–470

Article  PubMed  Google Scholar 

Straube A, Broessner G, Gaul C et al (2023) Real-world effectiveness of fremanezumab in patients with migraine switching from another mAb targeting the CGRP pathway: a subgroup analysis of the finesse study. J Headache Pain 24:59

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ziegeler C, Mehnert J et al (2020) Central effects of erenumab in migraine patients: an event-related functional imaging study. Neurology 95:e2794–e2802

Article  CAS  PubMed  Google Scholar 

Basedau H, Sturm LM et al (2022) Migraine monoclonal antibodies against CGRP change brain activity depending on ligand or receptor target - an fMRI study. Elife 11:e77146

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hong JB, Lange KS, Overeem LH, Triller P, Raffaelli B, Reuter U (2023) A scoping review and meta-analysis of anti-CGRP monoclonal antibodies: predicting response. Pharmaceuticals (Basel) 16(7):934

Article  CAS  PubMed  Google Scholar 

Nowaczewska M, Straburzyński M, Waliszewska-Prosół M, Meder G, Janiak-Kiszka J, Kaźmierczak W (2022) Cerebral blood flow and other predictors of responsiveness to erenumab and fremanezumab in migraine-a real-life study. Front Neurol 13:895476

Article  PubMed  PubMed Central  Google Scholar 

Yuan H, Spare NM, Silberstein SD (2019) Targeting CGRP for the prevention of migraine and cluster headache: a narrative review. Headache 59(Suppl 2):20–32

Article  PubMed  Google Scholar 

Moreno-Ajona D, Pérez-Rodríguez A, Goadsby PJ (2020) Gepants, calcitonin-gene-related peptide receptor antagonists: what could be their role in migraine treatment? Curr Opin Neurol 33(3):309–315

Article  CAS  PubMed  Google Scholar 

Lipton RB, Croop R, Stock DA, Madonia J, Forshaw M, Lovegren M et al (2023) Safety, tolerability, and efficacy of zavegepant 10 mg nasal spray for the acute treatment of migraine in the USA: a phase 3, double-blind, randomised, placebo-controlled multicentre trial. Lancet Neurol 22(3):209–217

Article  CAS  PubMed  Google Scholar 

Croop R, Lipton RB, Kudrow D, Stock DA, Kamen L, Conway CM et al (2021) Oral rimegepant for preventive treatment of migraine: a phase 2/3, randomised, double-blind, placebo-controlled trial. Lancet 397(10268):51–60

Article  CAS  PubMed  Google Scholar 

Ailani J, Lipton RB, Goadsby PJ, Guo H, Miceli R, Severt L, Finnegan M, Trugman JM, ADVANCE Study Group (2021) Atogepant for the preventive treatment of migraine. N Engl J Med 385(8):695–706. https://doi.org/10.1056/NEJMoa2035908. (PMID: 34407343)

Article  CAS  PubMed  Google Scholar 

Pan KS, Siow A, Hay DL, Walker CS (2020) Antagonism of CGRP signaling by rimegepant at two receptors. Front Pharmacol 11:1240. https://doi.org/10.3389/fphar.2020.01240. (PMID: 32973499; PMCID: PMC7468408)

Article  CAS  PubMed  PubMed Central  Google Scholar 

Goadsby PJ, DD, Trugman JM, Finnegan M, Lakkis H, Lu K, et al (2019) Orally Administered Atogepant Was Efficacious, Safe, and Tolerable for the Prevention of Migraine: Results From a Phase 2b/3 Study 92(15 Supplement):S17.001

Luo G, Chen L, Conway CM, Denton R, Keavy D, Signor L et al (2012) Discovery of (5S,6S,9R)-5-amino-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-9-yl 4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxylate (BMS-927711): an oral calcitonin gene-related peptide (CGRP) antagonist in clinical trials for treating migraine. J Med Chem 55(23):10644–10651

Article  CAS  PubMed  Google Scholar 

Moreno-Ajona D, Villar-Martínez MD, Goadsby PJ (2022) New generation gepants: migraine acute and preventive medications. J Clin Med 11(6):1656

Article  CAS  PubMed  PubMed Central  Google Scholar 

Schwedt TJ, Myers Oakes TM, Martinez JM, Vargas BB, Pandey H, Pearlman EM, Richardson DR, Varnado OJ, Cobas Meyer M, Goadsby PJ (2023) Comparing the efficacy and safety of galcanezumab versus rimegepant for prevention of episodic migraine: results from a randomized. Controlled Clinical Trial Neurol Ther. https://doi.org/10.1007/s40120-023-00562-w. (Epub ahead of print. PMID: 37948006)

Baker TE, Croop R, Kamen L, Price P, Stock DA, Ivans A, Bhardwaj R, Anderson MS, Madonia J, Stringfellow J, Bertz R, Coric V, Hale TW (2022) Human milk and plasma pharmacokinetics of single-dose rimegepant 75 mg in healthy lactating women. Breastfeed Med 17(3):277–282

Article  PubMed  PubMed Central  Google Scholar 

Schwedt TJ, Lipton RB, Ailani J, Silberstein SD, Tassorelli C, Guo H, Lu K, Dabruzzo B, Miceli R, Severt L, Finnegan M, Trugman JM (2022) Time course of efficacy of atogepant for the preventive treatment of migraine: results from the randomized, double-blind ADVANCE trial. Cephalalgia 42(1):3–11

Article  PubMed  Google Scholar 

Gao B, Yang Y, Wang Z, Sun Y, Chen Z, Zhu Y, Wang Z (2020) Efficacy and safety of rimegepant for the acute treatment of migraine: evidence from randomized controlled trials. Front Pharmacol 10:1577

Article  PubMed  PubMed Central  Google Scholar 

Goadsby PJ, Dodick DW, Ailani J, Trugman JM, Finnegan M, Lu K, Szegedi A (2020) Safety, tolerability, and efficacy of orally administered atogepant for the prevention of episodic migraine in adults: a double-blind, randomized phase 2b/3 trial. Lancet Neurol 19(9):727–737

Article  CAS  PubMed  Google Scholar 

Pohl H, Gantenbein AR, Sandor PS et al (2020) A survey on probable and improbable decisions about headache treatment. SN Compr. Clin Med 2:2245–2252. https://doi.org/10.1007/s42399-020-00556-x

Article  Google Scholar 

Singh A, Gupta D, Sahoo AK (2020) Acute migraine: can the new drugs clinically outpace? SN Compr. Clin Med 2:1132–1138. https://doi.org/10.1007/s42399-020-00390-1

Article  Google Scholar 

Schoenen J, Van Dycke A, Versijpt J, Paemeleire K (202